Inter-patient molecular heterogeneity is the major declared driver of an expanding variety of anticancer drugs and personalizing their prescriptions. Here, we compared interpatient molecular heterogeneities of tumors and repertoires of drugs or their molecular targets currently in use in clinical oncology. We estimated molecular heterogeneity using genomic (whole exome sequencing) and transcriptomic (RNA sequencing) data for 4890 tumors taken from The Cancer Genome Atlas database. For thirteen major cancer types, we compared heterogeneities at the levels of mutations and gene expression with the repertoires of targeted therapeutics and their molecular targets accepted by the current guidelines in oncology. Totally, 85 drugs were investigated, collectively covering 82 individual molecular targets. For the first time, we showed that the repertoires of molecular targets of accepted drugs did not correlate with molecular heterogeneities of different cancer types. On the other hand, we found that the clinical recommendations for the available cancer drugs were strongly congruent with the gene expression but not gene mutation patterns. We detected the best match among the drugs usage recommendations and molecular patterns for the kidney, stomach, bladder, ovarian and endometrial cancers. In contrast, brain tumors, prostate and colorectal cancers showed the lowest match. These findings provide a theoretical basis for reconsidering usage of targeted therapeutics and intensifying drug repurposing efforts.
Keywords: cancer drugs; chemotherapy; clinical oncology; genome; molecular diagnostics; mutations; personalized medicine; targeted therapeutics; transcriptome; tumor heterogeneity.
Conflict of interest statement
The authors declare no conflict of interest.
RNA sequencing for research and diagnostics in clinical oncology.Semin Cancer Biol. 2020 Feb;60:311-323. doi: 10.1016/j.semcancer.2019.07.010. Epub 2019 Aug 11. Semin Cancer Biol. 2020. PMID: 31412295 Review.
Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20. Eur Urol. 2018. PMID: 30033047
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.Eur Urol. 2019 Mar;75(3):498-505. doi: 10.1016/j.eururo.2018.08.009. Epub 2018 Sep 1. Eur Urol. 2019. PMID: 30181068
Clinical trials for precision oncology using next-generation sequencing.Per Med. 2013 Jul;10(5):485-495. doi: 10.2217/pme.13.36. Per Med. 2013. PMID: 29758837
Novel points of attack for targeted cancer therapy.Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):9-18. doi: 10.1111/bcpt.12313. Epub 2014 Oct 30. Basic Clin Pharmacol Toxicol. 2015. PMID: 25154903 Free PMC article. Review.